A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Fasinumab (Primary)
- Indications Back pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 14 Sep 2017 Status changed from planning to not yet recruiting.
- 14 Feb 2017 New trial record
- 09 Feb 2017 This trial is expected to begin in 2017, according to a Regeneron Pharmaceuticals media release.